CONTROLLED RELEASE FORMULATION FOR ADMINISTRATION OF AN ANTI-INFLAMMATORY NAPHTHALENE DERIVATIVE
申请人:——
公开号:US20020102309A1
公开(公告)日:2002-08-01
An anti-inflammatory pharmaceutical formulation for the oral administration of a nonsteroidal anti-inflammatory drug (NSAID) is provided, wherein the NSAID an anti-inflammatory naphthalene derivative such as nabumetone, 6-methoxy-2-naphthylacetic acid (6-MNA), a fluoronaphthylone, an amido-substituted naphthalene compound, or a nabumetone derivative comprising an acetal, enol acylate or enol ether of nabumetone. The formulation is controlled release, and a preferred formulation is an enterically coated, delayed release dosage form of nabumetone. Methods for using the novel formulation are provided as well; a preferred use is in the treatment of conditions and disorders associated with inflammation.
[EN] CONTROLLED RELEASE FORMULATION FOR ADMINISTRATION OF AN ANTI-INFLAMMATORY NAPHTHALENE DERIVATIVE<br/>[FR] PREPARATION A LIBERATION CONTROLEE DESTINEE A L'ADMINISTRATION D'UN DERIVE NAPHTALENE ANTI-INFLAMMATOIRE
申请人:COPLEY PHARMACEUTICAL INC
公开号:WO2001019350A1
公开(公告)日:2001-03-22
An anti-inflammatory pharmaceutical formulation for the oral administration of a nonsteroidal anti-inflammatory drug (NSAID) is provided, wherein the NSAID an anti-inflammatory naphthalene derivative such as nabumetone, 6-methoxy-2-naphthylacetic acid (6-MNA), a fluoronaphthylone, an amido-substituted naphthalene compound, or a nabumetone derivative comprising an acetal, enol acylate or enol ether of nabumetone. The formulation is controlled release, and a preferred formulation is an enterically coated, delayed release dosage form of nabumetone. Methods for using the novel formulation are provided as well; a preferred use is in the treatment of conditions and disorders associated with inflammation.
Fluoronaphthylones
申请人:Beecham Group Limited
公开号:US04243682A1
公开(公告)日:1981-01-06
4-(6-Substituted naphthyl)butan-2-ols,-butan-2-ones,-pentan-2-ols and -pentan-2-ones bearing a fluoro group in the naphthyl ring, and pro-drugs thereof, are anti-inflammatory agents. A typical embodiment is 4-(4-fluoro-6-methoxy-2-naphthyl)-butan-2-one.